
Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs
Although antibody-drug conjugates (ADCs) have been approved in select tumor types for years now, the 2024 tumor-agnostic approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for select patients has provided the first ever ADC option in many cancers …